RAKOVINA THERAPEUTICS INC (RKV.CA) Fundamental Analysis & Valuation

TSX-V:RKV • CA75103L3092

Current stock price

0.12 CAD
-0.01 (-7.69%)
Last:

This RKV.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RKV.CA Profitability Analysis

1.1 Basic Checks

  • RKV had negative earnings in the past year.
  • RKV had a negative operating cash flow in the past year.
  • RKV had negative earnings in each of the past 5 years.
  • RKV had a negative operating cash flow in each of the past 5 years.
RKV.CA Yearly Net Income VS EBIT VS OCF VS FCFRKV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

Industry RankSector Rank
ROA -158.75%
ROE -443%
ROIC N/A
ROA(3y)-53.87%
ROA(5y)-49.76%
ROE(3y)-70.85%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
RKV.CA Yearly ROA, ROE, ROICRKV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RKV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RKV.CA Yearly Profit, Operating, Gross MarginsRKV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. RKV.CA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, RKV has more shares outstanding
  • Compared to 5 years ago, RKV has more shares outstanding
  • RKV has a better debt/assets ratio than last year.
RKV.CA Yearly Shares OutstandingRKV.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M
RKV.CA Yearly Total Debt VS Total AssetsRKV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

  • RKV has an Altman-Z score of -10.45. This is a bad value and indicates that RKV is not financially healthy and even has some risk of bankruptcy.
  • RKV has a Debt/Equity ratio of 0.61. This is a neutral value indicating RKV is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z -10.45
ROIC/WACCN/A
WACCN/A
RKV.CA Yearly LT Debt VS Equity VS FCFRKV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M 6M 8M

2.3 Liquidity

  • A Current Ratio of 0.78 indicates that RKV may have some problems paying its short term obligations.
  • RKV has a Quick Ratio of 0.78. This is a bad value and indicates that RKV is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.78
RKV.CA Yearly Current Assets VS Current LiabilitesRKV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1M 2M 3M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. RKV.CA Growth Analysis

3.1 Past

  • The earnings per share for RKV have decreased strongly by -34.77% in the last year.
EPS 1Y (TTM)-34.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. RKV.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RKV. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RKV.CA Price Earnings VS Forward Price EarningsRKV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RKV.CA Per share dataRKV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RKV.CA Dividend Analysis

5.1 Amount

  • No dividends for RKV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RKV.CA Fundamentals: All Metrics, Ratios and Statistics

RAKOVINA THERAPEUTICS INC

TSX-V:RKV (3/13/2026, 7:00:00 PM)

0.12

-0.01 (-7.69%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-28
Earnings (Next)04-29
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.51%
Ins Owner ChangeN/A
Market Cap2.54M
Revenue(TTM)N/A
Net Income(TTM)-8.36M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS0.09
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.75%
ROE -443%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.87%
ROA(5y)-49.76%
ROE(3y)-70.85%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.78
Altman-Z -10.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.6%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-160.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-264.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-264.92%
OCF growth 3YN/A
OCF growth 5YN/A

RAKOVINA THERAPEUTICS INC / RKV.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RAKOVINA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to RKV.CA.


Can you provide the valuation status for RAKOVINA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to RAKOVINA THERAPEUTICS INC (RKV.CA). This can be considered as Overvalued.


How profitable is RAKOVINA THERAPEUTICS INC (RKV.CA) stock?

RAKOVINA THERAPEUTICS INC (RKV.CA) has a profitability rating of 0 / 10.


What is the financial health of RAKOVINA THERAPEUTICS INC (RKV.CA) stock?

The financial health rating of RAKOVINA THERAPEUTICS INC (RKV.CA) is 1 / 10.